Moderna Inc [MRNA] stock is trading at $27.82, up 1.31%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MRNA shares have gain 8.08% over the last week, with a monthly amount drifted -10.60%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Neutral rating and assigned the stock a price target of $40. Previously, Barclays downgraded its rating to Equal Weight on February 18, 2025, and dropped its price target to $45. On January 29, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $51 on the stock. Argus downgraded its rating to a Hold. Berenberg started tracking with a Hold rating for this stock on November 19, 2024, and assigned it a price target of $42. In a note dated November 18, 2024, HSBC Securities upgraded an Buy rating on this stock but restated the target price of $58.
Moderna Inc [MRNA] stock has fluctuated between $23.15 and $170.47 over the past year. Currently, Wall Street analysts expect the stock to reach $55.5 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $27.82 at the most recent close of the market. An investor can expect a potential return of 99.5% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
Moderna Inc [NASDAQ:MRNA] reported sales of 3.24B for the trailing twelve months, which represents a drop of -65.54%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -1.22%, Pretax Profit Margin comes in at -1.12%, and Net Profit Margin reading is -1.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.3 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.32 points at the first support level, and at 26.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.16, and for the 2nd resistance point, it is at 28.51.
Ratios To Look Out For
For context, Moderna Inc’s Current Ratio is 3.67. As well, the Quick Ratio is 3.62, while the Cash Ratio is 0.87. Considering the valuation of this stock, the price to sales ratio is 3.32, the price to book ratio is 0.99.
Transactions by insiders
Recent insider trading involved Bancel Stephane, Chief Executive Officer, that happened on Mar 03 ’25 when 0.16 million shares were purchased. Director, SAGAN PAUL completed a deal on Mar 03 ’25 to buy 31620.0 shares. Meanwhile, Chief Legal Officer Klinger Shannon Thyme sold 529.0 shares on Dec 09 ’24.
